Niger has become the latest West African country to roll out malaria vaccines to try to stifle the potentially deadly disease ...
The inoculation campaign is expected to lower the mortality rate in children, as malaria makes up 19 percent of child deaths ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
(Reuters) – British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with ...
GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...